A Green Voltammetric Determination of Molnupiravir Using a Disposable Screen-Printed Reduced Graphene Oxide Electrode: Application for Pharmaceutical Dosage and Biological Fluid Forms

A Green Voltammetric Determination of Molnupiravir Using a Disposable Screen-Printed Reduced Graphene Oxide Electrode: Application for Pharmaceutical Dosage and Biological Fluid Forms

A new green-validated and highly sensitive electrochemical method for the determination of molnupiravir (MOV) has been developed using cyclic voltammetry. The proposed analytical platform involves the use of a disposable laboratory-made screen-printed reduced graphene oxide 2.5% modified electrode (...

Full description

Bibliographic Details
Main Authors:	Abdelrahman Nabil, Hassan A. M. Hendawy, Randa Abdel-Salam, Rasha M. Ahmed, Ahmed Shawky, Samy Emara, Noha Ibrahim
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Chemosensors
Subjects:	molnupiravir cyclic voltammetry differential pulse disposable screen-printed electrode reduced grapheme oxide biological fluids
Online Access:	https://www.mdpi.com/2227-9040/11/9/471

Similar Items

Disposable Pencil Graphite Electrode for Diosmin Voltammetric Analysis
by: Iulia Gabriela David, et al.
Published: (2021-03-01)

Safety and Effectiveness of Molnupiravir in Covid-19 Treatment: A Rapid Review
by: Mohammadreza Mobinizadeh, et al.
Published: (2022-10-01)

Voltammetric Investigation of Ferulic Acid at Disposable Pencil Graphite Electrode
by: Iulia Gabriela David, et al.
Published: (2023-10-01)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
by: Michela Pontolillo, et al.
Published: (2022-09-01)

Can Tremor Be a Rare Side Effect Related to Molnupiravir?
by: Sinan MERMER, et al.
Published: (2022-11-01)

Computational Analysis of Molnupiravir
by: Artem V. Sharov, et al.
Published: (2022-01-01)

Efficacy and safety of molnupiravir in adult outpatients with COVID-19
by: Natalia Y. Pshenichnaya, et al.
Published: (2023-06-01)

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
by: Yuexiang Li, et al.
Published: (2022-05-01)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
by: Greta Santi Laurini, et al.
Published: (2022-12-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
by: Clara Weil, et al.
Published: (2023-08-01)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
by: Hikari Mizutani, et al.
Published: (2022-01-01)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
by: Zi-Xin Huang, et al.
Published: (2023-06-01)

Earth-friendly-assessed silver-nanoparticles spectrophotometric method for rapid and sensitive analysis of Molnupiravir, an FDA-approved candidate for COVID-19: application on pharmaceutical formulation and dissolution test
by: Ahmed R. Mohamed, et al.
Published: (2023-03-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

Why Molnupiravir Fails in Hospitalized Patients
by: Ashley N. Brown, et al.
Published: (2022-12-01)

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir
by: Omar Faruk, et al.
Published: (2024-01-01)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
by: Cheng SL, et al.
Published: (2023-01-01)

Voltammetric Behaviour of Hesperidin at a Composite Graphite Electrode
by: Nimet Numan, et al.
Published: (2020-11-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
by: Masahiro Kimata, et al.
Published: (2023-03-01)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
by: Matthew G. Johnson, et al.
Published: (2024-03-01)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2023-10-01)

Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
by: Kinga Czarnecka, et al.
Published: (2022-10-01)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
by: Ching-Chi Lee, et al.
Published: (2021-10-01)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
by: Divya Teli, et al.
Published: (2023-02-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
by: Nicolas Salvadori, et al.
Published: (2024-06-01)

Voltammetric Determination of Diethylstilbestrol in Pharmaceutical Formulation
by: Pâmela Caires de Oliveira, et al.
Published: (2019-09-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
by: Mohd. Imran, et al.
Published: (2021-09-01)

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
by: Shohei Shinozaki, et al.
Published: (2024-01-01)

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
by: Julie M. Strizki, et al.
Published: (2023-11-01)

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
by: Antonio Vena, et al.
Published: (2022-07-01)

Voltammetric study of polyphenolic compounds /
by: Salmiah Jamal Mat Rosid, 1988-, et al.
Published: (2010)

Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen
by: Yasmine Ahmed Sharaf, et al.
Published: (2022-04-01)

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
by: Cosmo Del Borgo, et al.
Published: (2023-04-01)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
by: Tommaso Lupia, et al.
Published: (2022-11-01)